Description
AZD-7762 is an inhibitor of checkpoint kinase 1 (Chk1) that increases sensitivity to DNA-damaging compounds. AZD-7762 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for a variety of cancers. In breast cancer and ovarian cancer cells, AZD-7762 inhibits cellular proliferation. In animal models of breast cancer, AZD-7762 inhibits tumor growth and increases survival rates. This compound displays somewhat limited efficacy due to cardiac toxicity.
References
Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014 Aug 7;14:570. PMID: 25104095.
Sausville E, Lorusso P, Carducci M, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):539-49. PMID: 24448638.
Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest. 2012 Apr;122(4):1541-52. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2702. PMID: 22446188.
